UK biotech Myricx Bio has raised £90 ($114) million Series A financing to support the development of its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) therapeutics. The round was co-led by new investors Novo Holdings and Abingworth, with additional support from British Patient Capital, Cancer Research Horizons and Eli Lilly, plus founding investors Brandon Capital and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!